Merit Medical Systems

MMSI

Market cap $4.21B

MMSI rides strong cardiovascular demand, therapeutic growth and innovation push, but tariffs, China pressure and OEM weakness cloud its near-term outlook.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Merit Medical acquires View Point Medical for $140M, boosting tumor detection tech and expanding its oncology portfolio with advanced localization solutions.

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock?

Exclusive agreement expands Medtronic's comprehensive pain interventions portfolio, increases treatment options for patients living with chronic pain GALWAY, Ireland, March 24, 2026 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, today announced that it has entered into a distribution agreement with Merit Medical Systems, Inc. (NASDAQ: MMSI), to offer FDA-cleared ViaVerte™ — a minimally invasive and implant free basivertebral nerve ablation (BVNA) system. It is the first and only BVNA system with a physician-controlled steerable mechanism for precise basivertebral nerve targeting for treating chronic vertebrogenic lower back pain.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Merit Medical launches Resilience TTS Esophageal Stent to address clinical gaps and expand its endoscopy portfolio with an advanced anti-migration design.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures